| CAI Qiang-jun,PAN Fu-rong,ZHANG Qi,et al.Effects of 131I treatment on the circulating granulocyte colony-stimulating factor and leucocyte levels in patients with Graves' disease[J].Chinese Journal of Radiological Medicine and Protection,2011,31(6):668-670 |
| Effects of 131I treatment on the circulating granulocyte colony-stimulating factor and leucocyte levels in patients with Graves' disease |
| Received:February 18, 2011 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.06.012 |
| KeyWords:Graves' disease Granulocyte colony-stimulating factor Leucopenia 131I treatment |
| FundProject:温州市"新世纪551人才工程"基金(551-02) |
|
| Hits: 4471 |
| Download times: 2437 |
| Abstract:: |
| Objective To observe the effects of 131I treatment on circulating granulocyte colony-stimulating factor (G-CSF) and leucocyte levels of patients with Graves' disease (GD). Methods Enzyme-linked immunosorbent assay (ELISA), coulter three assortments, and radioimmunoassay were used to test the levels of circulating G-CSF, leucocytes and thyroid hormones of 65 incipient and untreated GD patients, all females, aged 21-50, 43 with normal leucocyte level and 22 with leucopenia before and after 131I treatment. Thirty age-matched healthy female subjects were used as controls. Results Before 131I treatment, the serous G-CSF level of the GD patients with normal leucocyte level was (28.4±11.7)μg/L, significantly higher than that of the control [(18.3±6.98) μg/L, t=2.376,P<0.05]. The serous G-CSF level of the GD patients with leucopenia was (40.1±13.8) μg/L, significantly higher than that of the patients with normal leucocyte level (t=2.788,P<0.01) and that of the control (t=3.672, P<0.01). 180 d after the initiation of 131I treatment, the G-CSF level of the patients with normal leucocyte level was (18.9±8.32) μg/L, not significantly different from that of the normal controls, however, the G-CSF level of the GD patients with leucopenia was (25.7±11.5) μg/L, still significantly higher than that of the normal control (t=2.103, P<0.05). The serous G-CSF level was negatively correlated with the titer of leucocyte (r=-0.38, P<0.05), however, not significantly correlated with such clinical parameters, as free triiodothyronine (FT3), free thyroxine (FT4) and thyrotropin-stimulating hormone (TSH). Conclusions Abnormal increment of G-CSF is observed in the GD patients, which may be related to the decrease of leucocyte. Effectively suppressing the auto-immune status in the GD patients, 131I treatment is a safe and reliable therapy for GD patients with leucopenia and should be used as early as possible. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
